In this study, we investigated tumor specific expression and potential clinical associations for progranulin and its associated receptor sortilin, with the aim to identify optimal biomarkers for breast cancer progression and prognosis that could potentially be targeted by anti-sortilin based therapy. This evidence concerns the gene GRN and breast carcinoma.